This will determine the feasibility of applying latest delivery technologies to an existing oral rotavirus vaccine to make it thermostable for further opportunities.

[4] Hilleman Laboratories, in collaboration with Gotovax AB (a University of Gothenburg spin-off biopharmaceutical company), is seeking to create highly effective oral cholera vaccines at a considerably lower price than existing ones available in the market.

This vaccine is intended to be easy to use, with cross protection against enterotoxigenic Escherichia coli (ETEC) diarrhea and be optimized for a longer shelf life.

[6] Hilleman Laboratories has initiated a two-pronged strategy to develop low-cost combination vaccines for treatment of invasive meningococcal disease.

[7] Hilleman Laboratories has joined with Kolkata-based National Institute of Cholera and Enteric Diseases (NICED), an Indian Council of Medical Research (ICMR) organisation, to develop a vaccine against shigella, a bacterium that causes dysentery.